Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italian clinical research organizations Phidea and Marvin Research have completed a merger. The new company will be named Phidea Marvin and have legal and operating offices in Milan, Italy.
Subscribe to our email newsletter
The combined company will also continue to operate its offices in Madrid, Spain providing drug development services to companies in need of a single source for clinical research including design and management of pan-European clinical trials (Phase I – III), and post marketing studies (Phase IV).
Services offered by the new company will include all aspects of the clinical trial process including: protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing. Observational and epidemiological studies will also continue to be performed.
Vincenzo Cocuzza, Phidea-Marvin’s CEO, said: “We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and especially the US and will continue to look for strategic opportunities that allow us to realize our goals.”